Publication Name	World Journal of Gastroenterology
Manuscript ID	13169
Country	China

Received	2014-08-08 20:03
Peer-Review Started	2014-08-09 19:29
To Make the First Decision	2014-09-15 16:11
Return for Revision	2014-09-22 08:28
Revised	2014-10-05 11:36
Second Decision	2014-11-10 16:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-19 09:31
Articles in Press	2014-11-19 09:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-06 17:49
Publish the Manuscript Online	2015-03-19 16:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Jing Zhao, Hong Shen, Han-Guang Hu and Jian-Jin Huang
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81201640 Department of Education of Zhejiang Province of China Y201225802 Medical and Technology Plan of Zhejiang Province of China 2013KYA093
Corresponding Author	Jian-Jin Huang, MD, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jie-Fang Road, Hangzhou 310009, Zhejiang Province, China. hhjj@medmail.com.cn
Key Words	Epidermal growth factor receptor tyrosine kinase inhibitor; Gemcitabine; Icotinib; Metastatic pancreatic cancer; Regimen
Core Tip	Patients with advanced metastatic pancreatic cancer have a poor prognosis. Currently, treatments available in China are accompanied by high toxicity and cost, with minimal benefit. Icotinib is a newly developed oral epidermal growth factor receptor tyrosine kinase inhibitor, which was combined with standard gemcitabine therapy for treatment of metastatic pancreatic cancer in a 64-year-old male patient. This case report demonstrates that the novel regimen produced partial remission with marked shrinkage of the pancreatic mass. Thus, icotinib combined with gemcitabine may be a promising therapeutic alternative for metastatic pancreatic cancer.
Publish Date	2015-03-19 16:57
Citation	Zhao J, Shen H, Hu HG, Huang JJ. Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World J Gastroenterol 2015; 21(11): 3441-3446
URL	http://www.wjgnet.com/1007-9327/full/v21/i11/3441.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i11.3441

Full Article (PDF)	WJG-21-3441.pdf
Full Article (Word)	WJG-21-3441.doc
Manuscript File	13169-Review.docx
Answering Reviewers	13169-Answering reviewers.pdf
Copyright License Agreement	13169-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	13169-Language certificate.pdf
Peer-review Report	13169-Peer review(s).pdf
Scientific Misconduct Check	13169-CrossCheck.jpg
Scientific Editor Work List	13169-Scientific editor work list.pdf